MaxCyte, Inc., a cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, announced they are entering into a strategic platform license agreement.
[MaxCyte, Inc.]
